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On acquisition of an oncogenic mutation, primary human and mouse cells can enter 
oncogene-induced senescence (OIS). OIS is characterized by a stable proliferation arrest and 
secretion of pro-inflammatory cytokines and chemokines, the senescence-associated 
secretory phenotype (SASP). Proliferation arrest and the SASP collaborate to enact tumor 
suppression, the former by blocking cell proliferation and the latter by recruiting immune 
cells to clear damaged cells. However, the interactions of OIS cells with the immune system 
are still poorly defined. Here we show that engagement of OIS in primary human 
melanocytes, specifically by melanoma driver mutations NRASQ61K and BRAFV600E, 
causes expression of the MHC class II antigen presentation apparatus, via secreted IL1ß 
signaling and expression of CIITA, a master regulator of MHC class II gene transcription. In 
vitro, OIS melanocytes activate T cell proliferation. In vivo, non-proliferating, oncogene-
expressing melanocytes localize to skin-draining lymph nodes where they induce T cell 
proliferation and an antigen presentation gene expression signature. In patients, expression of 
MHC class II in melanoma is linked to favorable disease outcome. We propose that OIS in 
melanocytes is accompanied by an antigen presentation phenotype, likely to promote tumor 
suppression via activation of the adaptive immune system. 
 






Melanoma is a frequently fatal cancer originating from pigment producing melanocytes of the 
skin (Lo and Fisher, 2014). The most common mutations found in melanoma are those that 
activate the MAP-kinase signaling pathway, most notably in BRAF and NRAS (Lo and Fisher, 
2014). The same mutations are also commonly found in benign nevi (or moles) (Omholt et 
al., 2002, Pollock et al., 2003). However, benign nevi only rarely progress to cancer because 
oncogene-expressing nevus melanocytes are ultimately checked in a proliferation arrested 
stated, called oncogene-induced senescence (Munoz-Espin and Serrano, 2014). Nevus 
melanocytes express several molecular markers of senescence, including senescence-
associated ß-galactosidase (SA ß-gal) and tumor suppressor p16INK4a (p16) (Gray-Schopfer 
et al., 2006, Michaloglou et al., 2005, Pawlikowski et al., 2013, Suram et al., 2012). 
Interestingly, aggregates of apparently non-malignant, non-proliferative, p16-expressing, 
melanocytic nevus-like cells, in the absence of any concurrent or subsequent melanoma, have 
also been well documented in the skin draining lymph nodes of humans (Mihic-Probst et al., 
2003, Patterson, 2004).  
OIS is also characterized by a secretory program, the Senescence Associated 
Secretory Phenotype (SASP) (Acosta et al., 2008, Krtolica et al., 2001, Kuilman et al., 2008). 
The SASP has various functions in OIS, including reinforcement and maintenance of 
proliferation arrest (Acosta et al., 2008, Kuilman et al., 2008), and recruitment of 
macrophages, neutrophils and NK cells of the innate immune system to clear premalignant 
oncogene-expressing senescent cells (Xue et al., 2007). NK cells also clear senescent cells in 
response to other cell and tissue damaging stresses (Krizhanovsky et al., 2008, Soriani et al., 
2009). However, clearance of mouse hepatocytes expressing an activated NrasQ61K 
oncogene was also shown to depend on activation of adaptive immunity, specifically on 
CD4+ T cells (Kang et al., 2011). Typically, CD4+ T cells are activated in the secondary 
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lymphoid tissues, such as lymph nodes and spleen, by professional antigen presenting cells 
(APCs), such as dendritic cells (Trombetta and Mellman, 2005). Dendritic cells endocytose 
and process antigens in peripheral tissues, and then migrate via the lymphatic vessels to the 
lymph nodes where they activate CD4+ T cells by MHC class II-mediated antigen 
presentation to naïve T cells.  
How senescent cells can activate the adaptive immune systems has been a mystery. 
Here we show that OIS in melanocytes caused by activation of the RAS/MAP-kinase 
pathway is accompanied by dramatic upregulation of the MHC class II antigen presentation 
complex. Furthermore, melanocytes carrying either BrafV600E or NrasQ61K mutations re-
localize specifically to skin-draining lymph nodes in mouse models. We also present 
functional evidence that in the nodes oncogene-expressing non-proliferating melanocytes 
enact an antigen presentation function to activate the adaptive immune system. 
 
RESULTS 
Melanocytes express MHC class II upon oncogene-induced senescence initiated by 
melanoma driver mutations. 
As we and others previously showed (Michaloglou et al., 2005, Pawlikowski et al., 2013), 
ectopic expression of BRAFV600E in primary human melanocytes induces OIS. Indicative of 
senescence, BRAFV600E-expressing melanocytes upregulated SA ß-gal (Figure 1A, 1B), 
arrested DNA replication as determined by a lack of EdU incorporation (Figure 1B), and 
showed senescence-associated heterochromatin foci (SAHF) in the nucleus (Figure S1). 
We previously investigated the transcriptional changes of melanocytes undergoing 
OIS by whole genome microarray analysis and RNA-seq analysis (Pawlikowski et al., 2013). 
Comparing BRAFV600E expressing melanocytes against vector transduced and uninfected 
melanocytes we observed striking upregulation of MHC class II complex transcripts (Table 
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S1) (Figure 1C). The cell surface MHC class II complex is a heterodimer of  and ß 
polypeptides, for example HLA-DRA and HLA-DRB1, respectively. Antigen presentation 
also depends on expression of chaperones and accessory factors, such as HLA-DM, HLA-D0 
and CD74, which facilitate antigen processing, loading and presentation by the MHC class II 
complex (Trombetta and Mellman, 2005). We observed HLA-DRA and HLA-DRB, amongst 
the top changes (Table S1). In addition, related HLA-DQA, HLA-DQB, HLA-DPA and 
HLA-DPB were also upregulated, together with important antigen processing and 
presentation accessory molecules, such as HLA-DMA, HLA-DMB and invariant chain CD74 
(Tables S2 & S3). 
Upregulation of the major components of MHC class II mRNAs, HLA-DRA and 
HLA-DRB, was confirmed by real time-reverse transcription PCR (Figure 1D). Expression of 
BRAFV600E also enhanced expression of ectopic HLA-DRA and HLA-DRB GFP fusion 
proteins (Figure 1E). Since this increase is independent of the genes’ normal transcription 
control elements, this also suggests at least some level of post-transcriptional regulation. 
Expression of endogenous HLA-DR protein in melanocytes upon OIS was demonstrated by 
Western blot analysis (Figure 1F) and immunofluorescence (Figure 1G, S2). A significant 
fraction of HLA-DR was localized at the plasma membrane of senescent cells (Figure 1G, 
S2B), consistent with a role in antigen presentation. 
To establish whether BRAFV600E-associated MHC class II expression is cell type 
restricted, we transduced melanocytes, primary human fibroblasts (IMR90) and primary 
human epidermal keratinocytes with BRAFV600E or control vector (Figure 2A). In contrast 
to BRAFV600E transduced melanocytes, neither fibroblasts nor keratinocytes exhibited 
significant upregulation of MHC class II transcripts levels (Figure 2B). Furthermore, gene 
expression profiling of fibroblasts transduced with BRAFV600E revealed marked 
downregulation of proliferation-promoting genes and upregulation of inflammatory/SASP 
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genes characteristic of senescence (Figure S3), and confirmed no significantly upregulated 
MHC class II genes (Figure S4). These results together suggest that MHC class II induction is 
not a common feature of all primary cell types in response to OIS (fibroblasts) and/or 
oncogene expression (keratinocytes).  
 In addition to activated oncogenes, other triggers also initiate cell senescence. For 
example, so-called replicative senescence (RS) which results from excess rounds of cell 
division (Salama et al., 2014). To test whether MHC class II upregulation is common to 
different modes of senescence, we investigated RS melanocytes. Melanocytes were serially 
passaged until they ceased proliferation, and were confirmed to be RS by positive staining for 
SA ß-gal (Figure 2C, D), and lack of BrdU incorporation (Figure 2D). In contrast to 
BRAFV600E-mediated OIS, RS did not induce robust upregulation of HLA-DRA or HLA-
DRB as detected by qRT-PCR (Figure 2E). Finally, no MHC class II protein could be 
detected by Western blotting (data not shown). These findings suggest that MHC class II 
induction is specific to OIS in some cell types, and not RS. 
 To establish whether MHC class II upregulation in melanocytes is specific to 
activated BRAFV600E or also triggered by other perturbations of melanoma oncogenic and 
tumor suppressor pathways, melanocytes were transduced with activated oncogenes, 
HRASG12V and NRASQ61K, activated MEK1Q56P (Emery et al., 2009) and activated 
myrAKT, as well as 2 shRNAs to stably knockdown PTEN (Figure 2F).  Ectopic expression 
of each of these oncogenes and knockdown of PTEN resulted in senescence as determined by 
positive staining for SA ß-gal (Figure 2G left, and Figure S5) and lack of proliferation 
indicated by the absence of EdU incorporation (Figure 2G right). Expression of NRASQ61K, 
BRAFV600E and MEK1Q56P resulted in robust upregulation of both HLA-DRA and HLA-
DRB, while expression of HRASG12V gave rise to a significantly weaker upregulation of 
both. In marked contrast, myrAKT expression and PTEN knockdown did not result in 
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detectable HLA-DR upregulation (Figure 2H). In contrast to results reported here, PTEN 
knockdown has previously been reported to not cause induction of senescence (Vredeveld et 
al., 2012). There could be many reasons for this apparent discrepancy – genetic and/or 
epigenetic differences in the melanocytes, cell culture conditions and others. Regardless, 
these results suggest that, at least under conditions used here, MHC class II induction is 
specific to aberrant mitogenic signaling through the RAS/BRAF/ERK pathway, but not the 
PTEN-AKT signaling pathway.  
Since MHC class II induction in BRAFV600E mutant melanocytes occurs 
concomitantly with induction of senescence, we wished to elucidate whether MHC class II 
induction is dependent on known effectors of the senescence program. In human cells, an 
intact p53 or pRB tumor suppressor pathway is necessary for initiation and maintenance of 
the senescence program (Salama et al., 2014), and abolition of p53/pRB signaling by ectopic 
expression of SV40 T-antigen disrupts most, if not all, hallmarks of senescence (Shay et al., 
1991). To test whether MHC class II induction is abolished by ectopic expression of SV40 T-
antigen, we co-expressed BRAFV600E together with SV40 T-antigen (Figure 2I). As 
expected, T-antigen prevented the growth arrest and SA ß-gal staining associated with 
senescence in BRAF expressing melanocytes (Figure 2J and S6). Moreover, co-expression of 
SV40 T-antigen abolished virtually all of the MHC class II induction (Figure 2K). This 
suggests that MHC class II induction is not only initiated by expression of oncogenic 
BRAFV600E, but requires at least some elements of the p53 / pRB-dependent senescence 
effector pathways. 
 
MHC class II upregulation is mediated by an IL1ß-CIITA signaling loop. 
Even though expression of SV40 T antigen suppressed induction of HLA-DRA and HLA-
DRB (Figure 2I-K), it is well documented that MHC class II expression is typically found in 
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50-60% of freshly isolated melanoma (Taramelli et al., 1986). We exploited this observation 
from the melanocytic lineage to gain insight into candidate regulators of MHC class II in 
primary human melanocytes. We assessed the correlation between mRNA expression of 
HLA-DRA and HLA-DRB and all other genes in publicly available TCGA skin cutaneous 
melanoma gene expression datasets (http://cancergenome.nih.gov/). This showed that, across 
all these datasets, expression of both HLA-DRA and HLA-DRB correlated most strongly 
with other HLA molecules (e.g. HLA-DQ and HLA-DP), other molecules involved in antigen 
presentation (e.g. CD74), and CIITA, a transcription factor already known to drive expression 
of HLA-DRA and HLA-DRB in dendritic cells (Figure 3A, B) (Muhlethaler-Mottet et al., 
1997). Conversely, expression of CIITA correlated most strongly with expression of MHC 
class II antigen presentation molecules (Figure 3A, B). To confirm this correlation, we 
analyzed RNA-seq data from 7 different melanoma derived cell lines (Pawlikowski et al., 
2013) and found that CIITA transcript levels correlated strongly with HLA-DRA and HLA-
DRB levels across this panel of melanoma lines (Figure 3C). Moreover, we found that MHC 
class II induction in melanocytes upon BRAFV600E-mediated OIS is also accompanied by 
increased CIITA expression (Figure 3D). Like expression of MHC class II, oncogene-
induced expression of CIITA was abolished by SV40 T-antigen (Figure 3E). Consistent with 
upregulation of MHC class II in OIS melanocytes, but not other modes of senescence (Figure 
2), we did not observe upregulation of CIITA in OIS fibroblasts (Figure S4). Together, these 
data from melanoma tumors, cell lines and primary human melanocytes indicate that CIITA 
is a likely driver of HLA-DRA and HLA-DRB in OIS primary human melanocytes.  
In cells known to conditionally express CIITA, expression is frequently induced by 
extracellular ligands (Trombetta and Mellman, 2005). Significantly, naïve melanocytes 
exposed to medium from OIS melanocytes upregulated CIITA transcripts (Figure 4A), in 
conjunction with MHC class II expression (Figure 4A). To identify the extracellular factors 
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responsible for upregulation of CIITA and MHC class II expression, we probed conditioned 
medium with an antibody array. Medium from BRAFV600E OIS melanocytes contained 
increased amounts of inflammatory cytokines compared to conditioned medium from 
proliferating cells (Figure 4B and Table S4), including interleukin 1B (IL1ß) (in the form of 
either uncleaved pro-IL1ß or cleaved mature IL1ß), CCL7, CXCL5, CXCL1, VEGF and 
CCL5. The presence of one or more IL1ß (180 +/- 9 pg/ml, n=4) isoforms in the extracellular 
medium of OIS melanocytes was confirmed by ELISA (Figure 4C), and robust upregulation 
of IL1ß mRNA transcripts was detected by qPCR (Figure 4D). When added as recombinant 
proteins to primary human melanocytes, from a panel of secreted cytokines, only mature 
IL1ß was able to induce CIITA and MHC class II expression (Figure 4E), but without 
accompanying activation of senescence, as evidenced by lack of SA ß-gal staining and 
unimpeded DNA synthesis (Figure 4F). Conversely, partial knockdown of IL1ß using 3 
independent shRNAs (Figure 4G) reduced MHC class II induction by BRAFV600E (Figure 
4G). Although we have not formally confirmed secretion of cleaved mature IL1ß in this study 
(rather than uncleaved pro-IL1ß), previous studies have shown that OIS cells do secrete 
processed mature IL1ß (Acosta et al., 2013), and IL1 and IL1ß are key upstream regulators 
of the SASP (Acosta et al., 2013, Orjalo et al., 2009). In sum, consistent with these previous 
studies, our studies indicate a central role for extracellular IL1ß in induction of MHC class II. 
We next tested whether IL1ß-mediated upregulation of MHC class II also depends on 
CIITA. In support of this idea, stimulation of melanocytes with IFN, a well-known inducer 
of CIITA (Trombetta and Mellman, 2005), also upregulated expression of HLA-DRA and 
HLA-DRB (Figure S7). More pointedly, partial knockdown of CIITA using 2 different 
shRNAs (Figure 4H) inhibited HLA-DRA and HLA-DRB expression induced by 
recombinant IL1ß (Figure 4H). Knock down of CIITA with 2 different shRNAs also tended 
to decrease BRAFV600E-induced expression of HLA-DRA and HLA-DRB, and with the 
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most effective shRNA, the effect on HLA-DRB expression was significant (P<0.05) (Figure 
4I). The reduced effectiveness of CIITA knock down in blocking the effects of activated 
BRAF compared to IL1ß suggests that BRAFV600E can act via additional signaling effectors 
besides CIITA. Consistent with an IL1ß-CIITA-MHC II pathway, ectopic expression of 
CIITA was sufficient to induce expression of HLA-DRA and HLA-DRB, but not IL1ß, in 
melanocytes (Figure 4J). Together, these results indicate that IL1ß-induced expression of 
CIITA is a major pathway for expression of MHC class II in OIS melanocytes. Interestingly, 
BRAFV600E-expressing fibroblasts upregulate IL1ß, but neither CIITA nor MHC II (Figure 
S4). This suggests that functional coupling between IL1ß and CIITA occurs in OIS 
melanocytes, but not fibroblasts.  
 
Oncogene activation causes localization of melanocytes to lymph nodes and T cell 
activation.   
Previously a mouse model expressing activated NRASQ61K in melanocytes under control of 
a tyrosinase promoter (Tyr-NrasQ61K) was shown to be hyper pigmented due to an excess of 
melanocytes in the skin, but also to contain melanocytes in the lymph nodes (Ackermann et 
al., 2005). Extending this observation in these mice, we showed that infiltration of pigmented 
melanocytes occurs into skin draining (Figure 5A, inguinal and brachial) nodes, but not into 
non-skin draining nodes (Figure 5A, mesenteric) and spleen (Figure 5A, spleen). While IHC 
analysis showed melanotic material dispersed throughout the skin draining lymph nodes, 
particularly in older mice (Figure 5A), immunofluorescence analysis in lymph nodes of 
albino Tyr-NrasQ61K (but not wild type) mice showed cells expressing the melanocyte 
marker, DCT, and exhibiting dendritic features characteristic of melanocytes predominantly 
localized adjacent to the subcapsular sinus of the lymph node (Figure 5B and Figure S8A). 
Therefore, to some extent, the melanotic material in the interior cortex of the node might 
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reflect residual cell debris, including melanin (oxidized tyrosine polymers), after phagocytic 
digestion of melanocytes. To eliminate the possibility that localization of melanocytes to 
lymph nodes is unique to Tyr-NrasQ61K mice, we also confirmed in another mouse model of 
inducible BRAFV600E in melanocytes (Tyr-Cre-Er : LSL-BrafV600E) (Mercer et al., 2005) 
that 4 weeks after oncogene activation, predominantly in the skin of young adult mice 
(through topical application of tamoxifen), melanocytes also accumulated in skin-draining 
brachial and inguinal lymph nodes (Figure S8B).  
As noted previously (Ackermann et al., 2005), in comparison to wild type mice, the lymph 
nodes of Tyr- NrasQ61K mice were enlarged (Figure 5C and Figure S8C) and their size 
progressively increased over at least the first several months after birth (Figure 5C). 
Moreover, the Tyr-NrasQ61K mice exhibited more melanocytes in the nodes than the Tyr-
Cre-Er : LSL-BrafV600E mice (compare Figure 5A and S8B, NrasQ61K and BrafV600E), 
paralleling the relative numbers of melanocytes in the skin of each model (Ackermann et al., 
2005, Dhomen et al., 2009).   
To determine the proliferative status of the melanocytes in the lymph nodes we used 
2-color immunofluorescence to stain melanocyte-containing lymph nodes of wild type and 
Tyr-NRasQ61K albino mice for Ki67, a marker of cycling cells, and DCT, a marker of 
melanocytes. DCT-positive melanocytes in lymph nodes were invariably Ki67-negative, 
whereas large numbers of surrounding lymphocytes stained positive for Ki67 (Figure 5D). In 
fact, quantification of the cell fractions from the nodes, showed a massive expansion of non-
melanocyte (non-melanin containing) cells (Figure 5E, left) and of CD3+ T cells in particular 
(Figure 5E, right), suggesting that the melanocytes present in the lymph nodes, directly or 
indirectly, induce a marked activation and expansion of T cells in these nodes. In sum, the 
increase in lymph node size appears to result primarily from expansion of T cell populations 
in melanocyte-containing nodes.  
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T cell activation and proliferation can be stimulated by MHC class II-mediated 
antigen presentation (Trombetta and Mellman, 2005). To investigate whether MHC class II-
expressing melanocytes acquire the ability to activate T cells, we performed the mixed 
leukocyte reaction (MLR) in which antigen presenting cells stimulate proliferation of T cells. 
Indeed, BRAFV600E-expressing OIS melanocytes induced cell division in CSFE labeled 
CD3+ cells in vitro, much more efficiently than control melanocytes (2.3 fold, p<0.0001; 
Figure 5F-G). Although this assay using unpurified T cells does not allow us to attribute T-
cell activation to a direct physical interaction between T cells and MHC II on melanocytes, it 
does show that BRAFV600E mutant melanocytes are more able, either directly by physical 
interaction or indirectly via other cell types or secreted factors, to stimulate T-cells than are 
control melanocytes. 
To investigate whether melanocyte-containing lymph nodes of Tyr-NRasQ61K mice 
exhibited features of increased antigen presentation, we harvested RNA from lymph nodes 
and performed RNA-seq. This showed up and down regulation of approximately 577 and 423 
genes respectively (Figure S9). Remarkably, the top 5 gene ontologies represented in the 
upregulated genes of Tyr-NRasQ61K nodes reflected increased antigen presentation and 
associated processes, such as endocytosis and vesicle-mediated transport (Figure 5H,5I). In 
principle, T cell expansion and antigen presentation in lymph nodes of Tyr-NrasQ61K mice 
could be associated with immune activation or induction of immune tolerance, the latter by 
activation of Treg cells (Delacher et al., 2014). To distinguish between these possibilities, we 
stained lymph nodes for expression of FoxP3, a transcription factor expressed by Treg cells 
(Delacher et al., 2014). This did not reveal an increase in the frequency of Treg cells in lymph 
nodes from Tyr-NrasQ61K mice (Figure 5J). We conclude that oncogene-expressing, non-
proliferating primary melanocytes, directly or indirectly, facilitate an antigen presentation 
function and potential immune activation function in the lymph nodes. 
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To assess the significance of MHC class II expression in human melanocytic 
neoplasia, we mined human melanoma TCGA data comparing expression of CIITA, HLA-
DRA and HLA-DRB with patient survival. Remarkably, high expression of each of these 
genes predicted improved patient survival (Figure S10). Moreover, HLA-DRA and HLA-
DRB are both components of the recently defined “immune infiltration” gene expression 
signature that is associated with good prognosis in this disease ((TCGA, 2015), data not 
shown). Of course, at least part of the CIITA, HLA-DRA and HLA-DRB could be expressed 
by infiltrating immune cells themselves. However, previous studies have reported expression 
of HLA-DR on melanoma cells (Barbieri et al., 2011, Colloby et al., 1992, Pollack et al., 
1981), and we also confirmed expression of HLA-DRA, HLA-DRB and CIITA in a number 
of melanoma cell lines (Figure 3C). This underscores the importance of MHC class II 
expression in melanoma and is consistent with a tumor suppressor role for MHC class II.  
 
DISCUSSION 
Here we show that oncogene activation in primary human melanocytes is accompanied by 
upregulation of MHC class II antigen presentation molecules, and phenotypes and functions 
suggestive of an antigen presentation role in vivo. Upregulation of MHC class II molecules in 
OIS melanocytes is triggered by SASP factor IL1ß, followed by IL1ß-mediated upregulation 
of CIITA, a master regulator of MHC class II expression (Trombetta and Mellman, 2005).  
 Several observations suggest that MHC class II expression in oncogene-expressing 
melanocytes has a dedicated function. First, melanocytes are restricted to the skin draining 
nodes, suggesting that they reach the nodes specifically via the lymphatics, the normal route 
for migration of antigen-presenting dendritic cells, not non-specifically via the blood. Second, 
these cells do not appear to be malignant, as judged by the absence of proliferation and their 
routine occurrence in mice lacking any detectable melanoma. Both the NRas and Braf models 
  van Tuyn et al.  
 14
exhibit a long latency in progression to melanoma, of several months to more than a year 
(Ackermann et al., 2005, Dhomen et al., 2009).  In both models, melanocytes were detected 
in nodes months before any melanoma was detected and is expected (e.g. at 39 days old). As 
noted previously, aggregates of apparently non-malignant, non-proliferative, p16-expressing, 
melanocytic nevus-like cells, in the absence of any concurrent or subsequent melanoma, have 
also been reported in the skin draining lymph nodes of humans (Mihic-Probst et al., 2003, 
Patterson, 2004) (albeit not as frequently or markedly as observed in the Tyr-NrasQ61K  
mouse model). Third, oncogene-expressing primary melanocytes appear to promote 
activation of the immune system. Oncogene-expressing senescent melanocytes stimulated T 
cell proliferation in vitro in the MLR assay and localization of melanocytes to the nodes was 
accompanied by a large increase in node-resident CD3+ T cells. RNA-seq analysis of lymph 
nodes also revealed gene expression signatures characteristic of increased antigen 
presentation in the melanocyte-containing lymph nodes of Tyr-NrasQ61K mice. The increase 
in T cells was not accounted for by an overt increase in FoxP3-expressing tolerance-inducing 
Treg cells. In sum, while we cannot, of course, formally rule out the possibility that the node 
melanocytes are very early and/or failed micrometastases, the collective data from mice and 
humans at least suggest the possibility that oncogene-expressing pre-malignant melanocytes 
might be programmed to activate the adaptive immune system.  
 Other caveats should also be considered. In general, benign human nevi do not 
express MHC II, nor are they associated with immune infiltration (Campoli et al., 2012, Lyle 
et al., 2000).  By IHC, we also found that nevi only very rarely (<10%) express detectable 
MHC II. Conceivably, benign human nevi represent a subset of OIS melanocytes that have 
been selected for downregulation of MHC II via evasion of MHC II-mediated immune-
editing. In apparent contrast to the data presented here, Vemurafenib, a BRAFV600E 
inhibitor, was previously found to upregulate interferon-mediated MHC II expression in 
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A375 melanoma cells (Sapkota et al., 2013). A wider comparison of the functional 
relationship between BRAFV600E and expression of MHC II in transformed melanoma cells, 
as compared to primary OIS melanocytes primarily studied here, is justified.  
 Notwithstanding these caveats and the overall complexity of immune responses, 
comprised of intricate temporally and spatially controlled antagonistic and synergistic 
interactions between many cell types, these data suggest a model whereby oncogene-
expressing primary melanocytes upregulate expression of MHC class II via an IL1ß /CIITA 
autocrine loop. These melanocytes re-localize to the skin draining lymph nodes where they 
appear able to directly or indirectly stimulate proliferation of T cells. We propose that the 
ability of oncogene-expressing primary melanocytes to engage the adaptive immune system 
may facilitate tumor suppression. 
 
MATERIALS AND METHODS 
Details of materials and methods are available in SI Materials and Methods. 
 
Cell culture 
Lightly pigmented neonatal human epidermal melanocytes, human neonatal epidermal 
keratinocytes (both from Invitrogen) IMR90 fibroblasts (ATCC) were cultured according to 
supplier instructions. Infections with Lentiviral vectors were performed as described 
(Pawlikowski et al., 2013). In all experiments oncogene and control vector transduced cells 
were kept in culture under selection for 2 weeks before being assayed for senescence and 
gene expression. Alternatively melanocytes were cultured in medium supplemented with 10 
ng/ml recombinant growth factor listed in Figure 4E (all from Gibco) for 6 days. 
 
Genetically Modified Mouse strains 
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Mice carrying a tyrosinase promoter driven NrasQ61K gene (Tyr-NrasQ61K) have been 
described (Ackermann et al., 2005). Mice conditionally expressing the mutant BrafV600E 
gene under control of tyrosinase driven CRE-ER (Delmas et al., 2003) (Tyr-CRE-ER : LSL-
BrafV600E) have also been described (Dhomen et al., 2009). Albino mice carrying the Tyr-
NrasQ61K allele were generated by cross-breeding with the albino FVB/NJ (Taketo et al., 
1991) strain. Control wild type mice were littermate albino mice lacking the Tyr-NRasQ61K 
transgene. All experiments were carried out in compliance with UK Home Office guidelines 
at the Beatson Institute for Cancer Research (Home Office PCD 60/2607) under project 
license 60/4079. 
 
Microarray, RNA-seq and TCGA data 
Microarray and RNAseq analysis of melanocytes transduced with BRAF600E expression or 
control vectors has been described (Pawlikowski et al., 2013), sequences are available from 
www.ncbi.nlm.nih.gov/geo (accession no. GSE46818). 
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Figure 1. Melanocytes express MHC class II upon OIS. 
A. Staining for SA ß-gal activity (Blue) on vector or BRAF600E transduced melanocytes. 
Scale=100 µm. The time span of oncogene activation was kept at 2 weeks for all OIS 
experiments unless indicated otherwise. 
B. Quantification of EdU incorporation and SA ß-gal staining. Graph shows means +/- SD, 
n=3. 
C. Representative RNA-seq track showing HLA-DRA sequence reads for control and 
BRAFV600E transduced melanocytes. Y axis shows sequence tags per million tags; x axis 
shows position along the HLA-DRA gene (spanning 5,178 base pair), with boxed exons.  
D. Detection of HLA-DRA transcript levels by qRT-PCR analysis.  
E. Representative IF image of HLA-DRA-GFP (left three panels) and HLA-DRB-GFP (right 
three panels) fusion protein transduced melanocytes. GFP staining in green, staining for 
MHC class II in red and nuclei in blue. Scale bar = 200 µm. 
F. Western blot showing BRAF, beta-actin (ATCB) and MHC class II (HLA-DR) expression.  
G. Confocal IF image of stained for MHC class II (HLA-DR; red), and nuclei (Blue). Scale 
bar = 10 µm. 
All graphs show means +/- SD, n=4. 
 
Figure 2. Expression of MHC class II is specific to melanocytes and OIS.  
A. Western blot of BRAFV600E expression in melanocytes, keratinocytes and fibroblasts 
transduced with a vector encoding BRAFV600E (B) or control vector (V).  
B. HLA-DRA and HLA-DRB transcript levels detected by qRT-PCR analysis, in 
melanocytes (mel), fibroblasts (fib) or keratinocytes (ker). ND = no signal detected.  
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C. Staining for SA ß-gal activity in melanocytes in exponential growth phase (PD 26) or at 
replicative senescence (PD 43). Scale bar = 50 µm. 
D. Quantification of SA ß-gal and BrdU positive melanocytes. 
E. HLA-DRA and HLA-DRB transcript levels in melanocytes detected by qRT-PCR.  
F. Western blots of HRASG12V, NRASQ61K, BRAFV600E, MEKQ56P, myrAKT 
expression and knockdown of PTEN. 
G. Quantification of SA ß-gal staining (left) and EdU incorporation (right) of melanocytes 
transduced as indicated.  
H. HLA-DRA and HLA-DRB transcript levels detected by qRT-PCR of melanocytes 
transduced as indicated.  
I. Western blot showing expression of BRAFV600E and SV40 T-antigen.  
J. Quantification of SA ß-gal staining and EdU incorporation of melanocytes transduced with 
BRAFV600E and SV40 T-antigen.  
K. HLA-DRA and HLA-DRB transcripts detected by qRT-PCR.  
All graphs show means +/- SD, n=4. 
 
Figure 3. CIITA is a candidate regulator of MHC class II in OIS melanocytes.  
A. Whole transcriptome expression correlation network centered on CIITA generated from 
TCGA melanoma RNA-seq data. Genes are represented as nodes and a Pearson Correlation 
Coefficient (PCC) between two genes of at least 0.6 as an edge (n=375). CIITA is shaded 
dark red and HLA genes light red. The boxed highlighted region in left panel is shown in 
right panel. 
B. Scatter plots of TCGA melanoma RNA-seq data comparing the expression of CIITA 
versus HLA-DRA (left) and CIITA versus HLA-DRB1 (right), in 375 patients. 
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C. Representative UCSC tracks of library normalized RNA-seq expression at HLA-DRA, 
HLA-DRB1 and CIITA in 7 melanoma cell lines, melanocytes infected with BRAFV600E 
and uninfected melanocytes. Y axis shows sequence tags per million tags; x axis shows 
position along the HLA-DRA gene, with boxed exons.  
D. qRT-PCR analysis of CIITA transcript levels detected in melanocytes. Graph depicts 
means +/- SD, n=4.  
E. CIITA transcript levels detected by qRT-PCR. Graph depicts means +/- SD, n=4.  
 
Figure 4. Expression of MHC class II is controlled by an IL1ß-CIITA loop.  
A. qRT-PCR analysis of CIITA and HLA-DRA transcripts in melanocytes exposed to 
conditioned medium for 14 days, from mock, vector and BRAFV600E transduced 
melanocytes. Graphs depict means +/- SD, n=4. 
B. Heatmap of cytokines in conditioned culture medium. See Table S4 for fold change and 
significance in cytokine levels. 
C. Quantification by ELISA of IL1ß in conditioned culture medium. Graph shows mean +/- 
SD, n=4. (* p < 0.0001). 
D. qRT-PCR analysis of IL1ß transcripts. Graphs depict means +/- SD, n=4. 
E. CIITA, HLA-DRA and HLA-DRB transcripts detected by qRT-PCR of mock or cytokine 
treated melanocytes. Cells were cultured for 6 days in culture medium supplemented with 10 
ng/ml of the indicated cytokine. Graph depicts means +/- SD, n=3. 
F. Quantification of EdU incorporation and SA ß-gal staining of melanocytes. Graphs are 
means +/- SD, n=4. 
G. qRT-PCR analysis of IL1ß and HLA-DRA transcripts in melanocytes transduced with 
vector (V) or BRAFV600E (B) in combination with an shRNA to IL1ß or non-targeting 
control (NTC). Graphs depict means +/- SD, n=4. 
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H. qRT-PCR analysis of CIITA, HLA-DRA and HLA-DRB transcripts in melanocytes 
induced with vehicle or recombinant IL1ß and transduced with shRNAs against CIITA or 
non-targeting control (NTC). 
I. qRT-PCR analysis of CIITA, HLA-DRA and HLA-DRB transcripts in melanocytes 
transduced with vector or BRAFV600E and an shRNA against CIITA or non-targeting 
control (NTC). Graphs depict means +/- SD, n=4. * p<0.05. 
J. qRT-PCR analysis of CIITA, HLA-DRA, HLA-DRB and IL1ß transcript levels in 
melanocytes transduced with control vector (V), BRAFV600E (B) or CIITA (C) over 
expression vectors. Graphs depict means +/- SD, n=4. 
 
Figure 5. Oncogene expressing melanocytes localize to skin draining lymph nodes.  
A. H+E stained sections of lymph nodes and spleen of WT and Tyr-NrasQ61K mice. Scale 
bar = 100 µm. 
B. DCT (green)-expressing cells in lymph node. DAPI, blue. Sub S, subcapsular sinus. C, 
cortex. Scale bar = 100 µm. 
C. Inguinal lymph node size plotted against age of mouse. Each point is a single node (2 
nodes per mouse). 
D. Melanocytes detected by DCT (green) in lymph nodes of albino Tyr-NrasQ61K transgenic 
mice and cycling cells detected by Ki67 (red). Scale bar = 100 µm. 
E. Quantification of total non-melanocyte (non-pigmented, left) and CD3+ fraction (right) 
from pooled inguinal, brachial and axillary lymph nodes per mouse. Graph plots means +/- 
SD (n=3 per group). * 7.2 fold difference (p=0.0049). # 5.3 fold difference (p=0.0007). 
F. FACS analysis of CSFE levels in CD3+ cells after co-culture with WBCs (neg, solid line), 
WBCs incubated with LPS (LPS), and melanocytes transduced with vector or BRAFV600E. 
The plot with the neg. sample also shows unstained WBCs (neg, dotted line). 
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G. Percentage of replicating CD3+ cells after induction with WBCs (neg), WBCs incubated 
with LPS (LPS), and vector or BRAFV600E transduced melanocytes. Bars represent means 
+/- SD, n=4. 
H. Table of the 5 most enriched gene ontologies (FDR <=5%) for genes that are upregulated 
by RNA-seq (FDR <= 5%) in Tyr-NrasQ61K over WT lymph nodes. 
I. Column clustered heatmap of all genes in the ontologies given in H) for WT and Tyr-
NrasQ61K lymph nodes. Genes are given by column and samples by row. The color intensity 
represents column Z-Score, where red indicates more highly expressed, and blue more lowly 
expressed genes. 
J. Representative Foxp3 staining (brown) of albino WT and Tyr-NrasQ61K mice. Nuclei are 
counterstained with hematoxylin (blue). Scale bar represents 50 µm. Quantification of the 
number of positive cells in 2 NRAS61K mice and 2 WT littermates, by calculating the 
average number positive cells from 2 slides per lymph node and counting 3 lymph nodes (2 
Inguinal, 1 brachial) per mouse, showed no significant difference between the nodes (160.8 
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Term ID Term Name Count Fold Enrichment FDR
GO:0050764 regulation of phagocytosis 6 10.49 0.37%
GO:0045807 positive regulation of endocytosis 6 7.71 1.62%
GO:0048002 antigen processing and presentation of peptide antigen 6 7.49 1.85%
GO:0030100 regulation of endocytosis 8 6.72 0.28%
GO:0060627 regulation of vesicle-mediated transport 9 4.74 1.00%
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Table S1. Top 20 changes between BRAFV600E and control melanocytes, determined 
by Affymetrix array and RNAseq. 
Affimetrix array1 RNAseq2
Gene Symbol UniGene ID 
fold 
change p (Holm) Gene Symbol locus 
fold 
change 
IL1B Hs.126256 1798 5.80E-04 IL1B chr2:113303654-113310988 28701 
AREG Hs.270833 1603 7.04E-03 C3 chr19:6628590-6671684 13965 
HLA-DRA Hs.520048 1384 6.57E-04 HLA-DRB1/5 chr6:32549180-32742436 6786 
INHBA Hs.583348 1289 5.58E-03 SERPINB2 chr18:59705918-59722158 6552 
NPTX2 Hs.3281 1094 2.69E-03 AL121995.1/3 chr1:119778820-119903801 5922 
TFPI2 Hs.438231 1087 9.02E-05 NPTX2 chr7:98099076-98099888 5333 
TGFBI Hs.369397 981 2.20E-04 HLA-DRA chr6:32515610-32520802 5200 
EREG Hs.115263 886 3.95E-02 TNC chr9:116821716-116920290 2761 
HLA-DRB1/4 Hs.696211 883 1.21E-03 SAA1 chr11:18244360-18248092 2682 
INHBA Hs.583348 843 1.78E-03 TAGLN3 chr3:113200936-113215425 2289 
C3 Hs.529053 772 2.95E-03 INHBA chr7:41691160-41709216 1911 
SERPINB2 Hs.594481 719 1.86E-02 TAC1 chr7:97199176-97207721 1885 
TFPI2 Hs.438231 654 1.25E-02 HLA-DQB1 chr6:32549180-32742436 1762 
COL22A1 Hs.117169 627 1.84E-03 MMP10 chr11:102146454-102156555 1690 
CXCR4 Hs.593413 620 1.02E-01 TFPI2 chr7:93349289-93358297 1571 
STC1 Hs.25590 613 9.92E-03 LCE1F chr1:151017002-151017127 1560 
ANGPTL4 Hs.9613 571 8.94E-02 MYH15 chr3:109646173-109646434 1402 
RTN1 Hs.368626 568 8.39E-03 COL22A1 chr8:139707615-139995421 1327 
STC1 Hs.25590 553 3.47E-04 EREG chr4:75449369-75473334 1263 
ANGPTL4 Hs.9613 571 8.94E-02 PRSS3 chr9:33740483-33789331 1244 
BRAFV600E and control melanocytes were kept in culture under selection for 1 week before 
being assayed for senescence and gene expression as described (Pawlikowski et al., 2013), 
using either Affymetrix array (n=3) or RNA-seq (n=1). The full dataset can be obtained from 
www.ncbi.nlm.nih.gov/geo (accession no. GSE46818). See also Table S2 and S3 for Antigen 
presentation related transcript changes, detected by Affymetrix array and RNA-seq 
respectively. 
1N=3 replicates. 2N=1 replicate. 
  




Table S2 . Antigen presentation related transcript changes between BRAFV600E and 
control melanocytes, determined by Affymetrix array. 
 
Gene symbol fold change1,2 p (Holm) 
IL1ß 1797.5 0.001 
HLA-DRA 1384.4 0.001 
HLA-DRB1/4 883.2 0.001 
CD74 250.8 0.016 
HLA-DQB1 240.1 0.104 
IL1A 237.8 0.002 
BRAF 191.9 0.004 
HLA-DRB1/3/4 182.9 0.018 
IL8 158.0 0.134 
IL11 130.7 0.016 
HLA-DQA1 95.6 0.014 
HLA-DMB 77.5 0.193 
HLA-DRB4 46.2 0.256 
IL33 32.2 1.000 
HLA-DRB6 29.9 1.000 
CTLA4 24.4 0.053 
CIITA 22.6 0.111 
HLA-DOA 15.8 0.107 
HLA-DPA1 14.4 0.387 
HLA-DMA 8.8 1.000 
ICAM1 6.6 1.000 
HLA-B 3.0 1.000 
HLA-DPB1 3.0 1.000 
HLA-DOB 1.8 1.000 
CD28 1.8 1.000 
HLA-F 1.4 1.000 
HLA-C 1.4 0.302 
HLA-E 1.3 1.000 
HLA-DQB2 1.2 1.000 
HLA-A 1.2 1.000 
HLA-G 1.1 1.000 
CD80 1.1 1.000 
ICAM5 1.1 1.000 
CD40 -1.1 1.000 
1N=3. 2Also see Table S3 for antigen presentation transcript changes detected by RNAseq. 











Table S3. Antigen presentation related transcript changes between BRAFV600E 
infected and control melanocytes, determined by RNAseq. 






























1N=1. 2Also see Table S2 for antigen presentation transcript changes detected by Affymetrix 
array. See Table S1 for additional information on the dataset.  




Table S4. Mean fold change of cytokine quantities between the conditioned culture 
medium of BRAFV600E and vector transduced melanocytes. 
Name Fold change P (Bh-fdr)1
IL1 beta 179.6  0.001
CCL7 131.8  0.001
CXCL5 100.1  0.000
CXCL1 alpha 64.0  0.000
VEGF 56.7  0.000
CCL5 33.0  0.035
CXCL1 10.8  0.000
IL8 8.3  0.000
IL6 4.2  0.008
GCSF 2.8  0.004
MCSF 1.9  0.490
CCL2 1.8  0.004
IL1 alpha 1.8  0.164
CCL8 1.6  0.617
IL7 1.6  0.459
INF gamma 1.3  0.620
IL2 1.3  0.557
CXCL9 1.2  0.396
IL12 1.1  0.593
IL3 1.1  0.798
CCL1 1.0  0.955
TGF beta1 1.0  0.955
ADAM11 1.0  0.836
TNF alpha 1.0  0.955
EGF 0.9  0.773
Angiogenin  0.9  0.121
IL13 0.9  0.891
CCL17 0.9  0.620
IL10 0.9  0.955
IL4 0.8  0.620
TNF beta 0.8  0.620
IL5 0.8  0.620
IGF1 0.8  0.955
Oncostatin M 0.8  0.463
PDGF BB 0.8  0.620
GM-CSF 0.8  0.754
SDF-1 0.7  0.955
CCL15  0.7  0.593
IL15 0.7  0.557
Leptin  0.5  0.251
Thrombopoietin  0.4  0.251
SCF 0.2  0.827
1Significance was calculated by students t-test with BH-fdr correction (n=4). Cytokine 
quantities in filtered culture supernatant from BRAFV600E and vector transduced 
melanocytes were determined using the human cytokine array G series 3 (Raybio). Culture 
supernatant was collected 2 weeks post transduction, and 2 days since the medium was last 
replaced. 
 





Table S5. Quality control data of the RNA-seq of mouse WT and NrasQ61K lymph 
nodes.  
Replicate ID Sample 
Raw Sequence 
reads Read Length 
Aligned Reads (% of Raw 
Sequence reads) 
Non-Duplicate Reads 
(% of Aligned Reads) 
46419 wt 10,004,588 72PE 9,480,699 (94.76%) 8,186,445 (86.35%) 
71309 wt 15,607,227 72PE 14,883,831 (95.36%) 13,392,117 (89.98%) 
71310 wt 15,929,113 72PE 15,230,797 (95.62%) 12,793,310 (84.00%) 
61600 NrasQ61K 13,785,721 72PE 12,808,334 (92.91%) 11,633,500 (90.83%) 
68718 NrasQ61K 10,221,677 72PE 6,967,111 (68.16%) 5,621,199 (80.68%) 




Table S6. Primer sequences used for reverse transcription-real time PCR analysis. 
Target Forward primer1 Reverse primer1 probe1 
hGAPDH ACACCCACTCCTCCACCTTT ATGAGGTCCACCACCCTGT ATTGCCCTCAACGACCACTTTGTC 
hACTB AGAAGGATTCCTATGTGGGCG CATGTCGTCCCAGTTGGTGAC CTCACCCTGAAGTACCCCATCGAG 
hCIITA CACTAACCACGCTGGACCTT GCAGAGCAAGATGTGGTTCA CTTCTCCAGGCTGTATCCCATGAGC 
hHLA-DRA CCCAACGTCCTCATCTGTTT AGCATCAAACTCCCAGTGCT AAGTTCACCCCACCAGTGGTCAAT 
hHLA-DRB GCACAGAGCAAGATGCTGAG GCAACCAGGTCCTGAGAAAG TCCTGAGCTGAAATGCAGATGACC 
hIL-1B GCTGAGGAAGATGCTGGTTC TCGTTATCCCATGTGTCGAA TCCAGGAGAATGACCTGAGCACCTTC 
mACTB AGCCATGTACGTAGCCATCC GCTGTGGTGGTGAAGCTGTA CATCTACGAGGGCTATGCTCTCCCT 
mH2-Ab1 CCTGGTGACTGCCATTACCT ACGTACTCCTCCCGGTTGTA TCGTGTACCAGTTCATGGGCGA 
1All sequences are given 5’ to 3’. 
 
  





Figure S1. Nuclei of senescent melanocytes display senescence-associated 
heterochromatin foci (SAHF). 










Figure S2. Immunofluorescent microscopy of HLA-DR expression on BRAFV600E 
expressing melanocytes. 
A. Lower magnification overview IFM image of vector and BRAFV600E transduced 
melanocytes, showing DAPI stained nuclei in blue, and HLA-DR in red. Scale=100 µm. 
B. Confocal IFM image of vector control and BRAFV600E expressing melanocytes, showing 
membrane localization of HLA-DR. Scale=100 µm. 
 









Figure S3. IMR90 fibroblasts expressing BRAFV600E display transcription profiles in 
compliance with senescence. 
Correlation clustered heatmap of a curated list of known proliferation, inflammation and 
senescence associated secretory phenotype (SASP) genes.  The colour intensity represents 
column Z-score, with red indicating high and blue low expression. The IMR90 fibroblasts 
were assayed 1 week after infection with BRAFV600E or control vectors. 
  






Figure S4. IMR90 fibroblasts show IL1B, but not CIITA or HLA-DRA, transcripts 
upon BRAFV600E expression. 
Normalized RNAseq plots showing transcripts for the IL1B, CIITA and HLA-DRA genes, in 
IMR90 fibroblasts expressing either vector control or BRAFV600E. The IMR90 fibroblasts 
were assayed 1 week after infection with BRAFV600E or control vectors. 
  








Figure S5. Oncogene induced senescence in melanocytes is accompanied by expression 
of senescence associated beta-galactosidase expression. 
Representative staining for SA beta-galactosidase activity of melanocytes transduced with 
control vector, HRASG12V, NRASQ61K, BRAFV600E, MEKQ56P, myrAKT over-expression 
vectors and 2 different PTEN knockdown vectors for the quantified SA-Bgal counts shown in 
Figure 2G. Scale = 50 m. 
 





Figure S6. SV40 T-antigen can drive proliferation of melanocytes irrespective of mutant 
BRAFV600E presence. 
A. Plot showing average percentage (n=3 +/- SD) of EdU positive melanocytes co-expressing 
SV40-T antigen and either vector (control) or BRAFV600E. 










Figure S7. Interferon gamma induces CIITA and HLA-DR in melanocytes. 
CIITA, HLA-DRA and HLA-DRB transcript levels detected by qRT-PCR analysis of mock 































































Figure S8. NrasQ61K and BrafV600E mutant melanocytes are present in skin draining 
lymph nodes. 
A. Dendritic DCT (green)-expressing cells (presumptive melanocytes) adjacent to the 
subcapsular sinus of the lymph node. DAPI, blue. Scale bar = 100 m.  
B. Haematoxylin and eosin stained sections of skin draining (inguinal and brachial) lymph 
nodes, non-skin draining (mesenteric) lymph nodes and spleen of WT and Tyr-CRE-ER : 
LSL-BrafV600E mice. Note the pigment in the inguinal and brachial nodes. Scale bar = 100 
m. 
C. Representative image of prepared inguinal lymph nodes from a WT mouse and a Tyr-
NrasQ61K mouse, which expresses NRASQ61K under the control of the tyrosinase promoter 
in melanocytes. 
  





Figure S9. Differentially expressed genes between WT and Tyr-NrasQ61K lymph nodes. 
Column clustered heatmap of differentially expressed genes (FDR <= 5%) between WT and 
Tyr-NrasQ61K lymph nodes. Genes are given by column and samples by row. The color 
intensity represents column Z-Score, where red indicates more highly expressed, and blue 
more lowly expressed genes. Heatmap shows up and down regulation of approximately 577 











Figure S10. Skin cutaneous melanoma patient survival correlates with MHC II 
expression. 
Kaplan Meier Curves of 10 year skin cutaneous melanoma patient survival (data from 
TCGA). Patients in the upper and lower quartiles of CIITA (left), HLA-DRA (middle) and 
HLA-DRB1 (right) expression are shown by the red and blue lines respectively (p<0.001, 









EXPANDED MATERIALS AND METHODS 
 
Cell culture 
Multiple batches of different lots of Lightly pigmented neonatal human epidermal 
melanocytes (Invitrogen) were cultured in medium 254 with human melanocyte growth 
supplement (HMGS), 100 U/ml penicillin and 100 µg/ml streptomycin (all from Invitrogen). 
Multiple batches of different lots of Human neonatal epidermal keratinocytes were cultured 
in EpiLife medium with human keratinocyte growth supplement, 100 U/ml penicillin and 100 
µg/ml streptomycin (all from Invitrogen). Keratinocytes were cultured on collagen 
(Invitrogen) coated plates.  IMR90 fibroblasts were obtained from ATCC and cultured in 
DMEM, supplemented with 20 % (v/v) fetal bovine serum, 100 U/ml penicillin and 100 
µg/ml streptomycin (all from Invitrogen). 
 
Lentivirus vector construction, production and infection 
Lentivectors encoding CIITA, HRASG12V, NRASQ61K, BRAFV600E, MEK1Q56P, 
myrAKT, SV40 T-antigen or short hairpins directed against PTEN, CIITA and IL-1B, under 
the transcriptional control of the cytomegalovirus initial early promoter and puromycin or 
neomycin resistance from the simian virus 40 promoter were generated using standard 
methods; details available upon request. Vesicular stomatitis virus G pseudotyped lentivector 
stocks were produced as described previously (van Tuyn et al., 2007). Melanocytes, 
keratinocytes and IMR90 fibroblasts were infected overnight in normal culture medium 
supplemented with 2 (melanocytes and keratinocytes) and 8 µg/ml polybrene, respectively 
overnight.  Followed by 14-32 days of culture in the presence of 1 µg/ml puromycin or 250 
µg/ml G418S (Invitrogen) to select for transduced cells. 




In all experiments oncogene and control vector transduced cells were kept in culture 
under selection for 2 weeks before being assayed for senescence and gene expression as 
detailed below, unless stated otherwise. 
 
Microarray, RNA-seq and analysis of TCGA data 
Microarray and RNAseq analysis of melanocytes transduced with BRAF600E expression or 
control vectors has been described (Pawlikowski et al., 2013), sequences can be obtained 
from the Gene Expression Omnibus (GEO) database, www.ncbi.nlm.nih.gov/geo (accession 
no. GSE46818). 
 
Induction of melanocytes with conditioned medium 
Cell culture supernatant was collected from BRAFV600E, vector or mock transduced 
melanocytes cultured in parallel at 2 weeks post transduction, and 2 days since the medium 
was last replaced (n=4 each). Vector transduced cultures were split several times to keep 
cultures at approximately the same number of cells. Culture supernatant was cleared by 
centrifugation at 3000 g for 10 minutes, followed by filtration through a 0.22 µm 
nitrocellulose membrane filter (Elkay), and frozen at -20°C until used in subsequent coculture 
experiments. 
For the coculture experiments fresh melanocytes were cultured in parallel in a mixture of half 
normal culture medium as described above and half conditioned medium from either 
BRAFV600E, vector or mock transduced melanocytes (n=4 each). Medium was refreshed 
every 2 days, for a total of 2 weeks, at which time cells were harvested for RNA and RT-PCR 
analysis. 
 
Induction of melanocytes with recombinant cytokines 




Melanocytes were cultured in normal melanocyte growth medium (as described above), 
supplemented with 10 ng/ml of recombinant human Interleukin 1, beta (IL1B) (Gibco; 
PHC0816), recombinant human Vascular Endothelial Cell Growth Factor (VEGF) (Gibco; 
PHC9394), recombinant human Chemokine (C-X-C motif) ligand 1 (CXCL1) (Gibco; 
PHC1066), recombinant human RANTES (alternative name: CCL5) (Gibco; PHC1054), 
recombinant human Epithelial Neutrophil Activating Peptide-78 (ENA78, alternative name: 
CXCL5) (Gibco; PHC1336), or recombinant human Monocyte chemotactic protein 3 (MCP-
3, alternative name: CCL7) (Gibco; PHC1574). Cells were cultured for 6 days in cytokine 
supplemented culture medium, which was refreshed every two days. 
 
Genetically Modified Mouse strains 
Animals were kept in conventional animal facilities and monitored frequently. All 
experiments were carried out in compliance with UK Home Office guidelines at the Beatson 
Institute for Cancer Research mouse facility (Home Office PCD 60/2607) under project 
license 60/4079. Mice were genotyped by PCR analysis. Mice carrying a tyrosinase promoter 
driven NrasQ61K gene (Tyr-NrasQ61K) have been described (Ackermann et al., 2005). Mice 
conditionally expressing the mutant BrafV600E gene under control of tyrosinase driven CRE-
ER (Delmas et al., 2003) (Tyr-CRE-ER : LSL-BrafV600E) have also been described (Dhomen 
et al., 2009). Albino mice carrying the Tyr-NrasQ61K allele were generated by cross-
breeding with the albino FVB/NJ (Taketo et al., 1991) strain. Control wild type mice were 
littermate albino mice lacking the Tyr-NRasQ61K transgene. 
 
Reverse transcription-quantitative polymerase chain reaction analysis 
Total RNA was isolated using the RNeasy mini spin kit with DNAse treatment (QIAGEN). 
Total cDNA was generated using SuperScript III (Invitrogen) from 0.1 - 5 µg RNA using 




random hexamers (Invitrogen), according to manufacturer instructions. Real-time qPCR was 
performed on 1/50th of the cDNA, using the primers and FAM-labeled probes (IDT 
technologies) described in Supplemental Table S6. Reactions were performed on the 
Chromo4 PCR machine (Biorad), using platinum Taq, and dNTPs from Invitrogen. 
Transcript levels were quantified using standard curves of known quantities of plasmid DNA 
and normalized against the geometric mean of GAPDH and ß-actin (ACTB) gene transcripts. 
 
Immunofluorescence microscopy 
Cells were plated on glass coverslips and cultured at least 24 hours prior to fixation with 4% 
neutral buffered formaldehyde for 15 minutes at room temperature. Samples were washed 3 
times with PBS, permeabilized with 0.1% triton in PBS for 5 minutes, followed by a further 3 
washes with PBS. Cells were blocked for 30 minutes at ambient temperature with 4% bovine 
serum albumin and 0.02% sodium azide in PBS (blocking solution), followed by 1 to 24 hour 
labeling with anti HLA-DR (L243; Abcam) at 1 µg/ml in blocking solution at 4 °C. After 3 
washes with PBS, cells were labeled with appropriate Alexa568 conjugated secondary 
antibodies (Invitrogen) in blocking solution for 1 hour at ambient temperature. Finally 
samples were washed 4 times with PBS and mounted in prolong gold with DAPI 
(Invitrogen). Images were acquired on the Nikon eclipse 80i fluorescent microscope, and the 
Olympus Fluoview 1000 IX81 confocal microscope. 
 
Cytokine array 
Culture supernatant from BRAFV600E and vector control transduced melanocytes was 
collected 2 weeks post transduction, and 2 days since the medium was last replaced. Culture 
supernatant was cleared by centrifugation at 3000 g for 10 minutes, followed by filtration 
through a 0.22 µm nitrocellulose membrane filter (Elkay). Cytokine quantities were 




determined using the human cytokine array G series 3 (Raybio), according to manufacturer 
recommendations. Images were acquired on the Scanarray Express (Perkin Elmer). 
 
ELISA 
The human IL-1ß ESILA Kit from Thermo Scientific (EH2IL1ß) was used to measure the 
levels of IL1ß in the culture supernatants of Melanocytes transduced with BRAF600E or 
control vector following manufacturer instructions. 
 
Immunohistochemistry 
H&E staining and immunohistochemistry was performed as previously described 
(Pawlikowski et al., 2013), using antibodies against DCT (Santa Cruz, sc-10451), FOXP3 
(Abcam, ab54501) and Ki67 (Vector labs, VP-K451). 
 
SA ß-gal and EdU assay 
SA ß-gal staining was performed as previously described (Pawlikowski et al., 2013). Staining 
for EdU incorporation was performed using the Click-iT EdU Alexa Fluor 594 Imaging kit 
(Invitrogen) according to manufacturer instructions, after a 72 hour pulse with EdU. Note that 
for all EdU experiments, a somewhat long 72 hour EdU pulse was used to truly be able to 
show a lack of proliferation in senescent cells, and to allow the generally slow proliferating 
primary cells (in the absence of BRAFV600E) used in this study to reach a significant 
percentage of EdU positive cells. 
 
FACS 
Fluorescence activated cell sorter (FACS) analysis was performed on a FACSCalibur system 
(Becton Dickinson), using standard methods. Where stated cells were stained with 5 µM 




CSFE or 1 µg/ml PI, or labeled with mouse anti CD3 conjugated to allophycocyanin 
(Biolegend). 
 
Mixed Leukocyte Reaction 
White blood cells were isolated according to standard protocols from excess human donor 
buffy coats using ficoll density gradient centrifugation, and labeled for 5 minutes with 5µM 
CSFE at room temperature. Unincorporated CSFE was removed by three washes with PBS. 
WBCs were plated at a density of 1x105 cells per well in 96-wells conical wells (not-cell 
culture treated). Melanocytes previously transduced with BRAFV600E or control vector were 
added to 5x105 cells per well. The co-cultures were maintained for 6 days in RPMI+10% 
FBS, medium was refreshed daily. FACS analysis was performed to assay WBC activity. 
 
TCGA Data 
The Cancer Genome Atlas (TCGA) skin cutaneous melanoma normalized RNA-seq V2 data 
was downloaded from TCGA data portal (http://cancergenome.nih.gov/).  
 
Expression correlation network of TCGA skin cutaneous melanoma data 
To generate the expression correlation network (ECN) from the TCGA skin cutaneous 
melanoma RNA-seq V2 data (Fig 3A), firstly a matrix of expression values by gene (n = 
20,531) and patient (n = 375) was generated. Next for each pairwise combination of genes, 
the Pearson Correlation Coefficient (PCC) of expression values across all patients was 
calculated. Next, to reduce the number of potentially meaningless connections two filtering 
steps were applied: Firstly, correlations between two genes below 0.6 were filtered out. 
Secondly, for each gene, correlations equal to or above 0.6 were ranked (highest first). 
Correlations that were not ranked amongst the top ten correlations of both genes were 




removed. Finally to generate the network, the resulting data was input into an equally 
weighted Fruchterman-Reingold force-directed algorithm, using a k value of 0.015 and 1000 
iterations. Genes were set as nodes and correlations between two genes as edges. 
 
RNA-seq of human Melanoma and Melanocyte cell lines 
Paired-end reads were aligned to the human genome (hg19) using a splicing-aware aligner 
(tophat2) (Kim et al., 2013). Reference splice junctions were provided by a reference 
transcriptome (Ensembl build 73), and novel splicing junctions determined by detecting reads 
that spanned exons that were not in the reference annotation. Bigwig files were generated 
from aligned reads using library size normalization, and uploaded to the UCSC genome 
browser (Kent et al., 2002). 
 
RNA-seq of mouse WT and NrasQ61K lymph nodes 
Inguinal lymph nodes were prepared from 350 day old Tyr-NrasQ61K mice and WT 
littermates. 
Total RNA was isolated using the RNeasy mini spin kit with DNAse treatment (QIAGEN). 
And prepared for RNAseq according to manufacturer instructions (Illumina) and as 
previously described (Pawlikowski et al., 2013). 
Paired-end reads were aligned to the mouse genome (mm10) using a splicing-aware aligner 
(tophat2) (Kim et al., 2013). RNAseq quality and control metrics have been listed in Table 
S5. Reference splice junctions were provided by a reference transcriptome (Ensembl build 
74), and novel splicing junctions determined by detecting reads that spanned exons that were 
not in the reference annotation. Aligned reads were processed to assemble transcript 
isoforms, and abundance was estimated using the maximum likelihood estimate function 




(cuffdiff) from which differential expression and splicing is derived (Trapnell et al., 2013). 
Genes of significantly changing expression were defined as FDR corrected p-value <0.05. 
 
RNA-seq Heatmaps 
For each gene of biotype coding and status known in the reference transcriptome (Ensembl 
build 74) the FPKM value was calculated based on aligned reads, using Cufflinks (Trapnell et 
al., 2013). Z-Scores were generated from FPKMs. Clustering was performed using the R 
library hclust2 and the Pearson method. 
 
Gene Ontology analysis using David 
Genes were uploaded to David (http://david.abcc.ncifcrf.gov), and a functional analysis 
performed using a background of Ensembl build 74 genes and the molecular functions GO 
terms. 
 
Kaplan Meier Curve of 10 year skin cutaneous melanoma patient survival 
The TCGA skin cutaneous melanoma normalized RNA-seq and patient clinical data was 
downloaded from the TCGA website (http://cancergenome.nih.gov/). Patients were filtered to 
include only those with both RNA-seq and clinical data, and a patient follow up date greater 
than 0. Patients were then grouped into quartiles by normalised CIITA, HLA-DRA and HLA-
DRB1 expression level. Kaplan Meier Curves were plotted for the upper and lower quartiles 
of expression, using the R-library: survival (version 2.38-3). P-values were calculated using 
the function coxph.  
 
Statistics 




Unless otherwise specified significance was calculated using Student's t-test and graphs 
depict means +/- standard deviation.  
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